Personalis, Inc. reported financial results for the quarter ended June 30, 2026, announcing total revenue of $22.4 million, a 30% increase from $17.2 million in the prior year period. Clinical test volume surged 199% year-over-year to 10,384 tests, driving clinical revenue growth of 442% to $2.6 million. The company secured Medicare coverage approvals for NeXT Personal for immunotherapy monitoring and neoadjuvant breast cancer monitoring. Core pharma testing services revenue rose 51% to $16.8 million, while population sequencing revenue declined 9% to $3.0 million. Personalis ended the quarter with approximately $212.7 million in cash, cash equivalents, and short-term investments. The company will no longer provide financial guidance following its merger agreement with Tempus AI announced on July 20, 2026. Personalis operates in the precision oncology industry, providing advanced genomic testing for cancer detection and monitoring.
